6wib: Difference between revisions

Line 1:

==Next generation monomeric IgG4 Fc==

== Structural highlights ==

<table><tr><td colspan='2'>Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=6WIB OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=6WIB FirstGlance]. <br>

<table><tr><td colspan='2'>[[6wib]] is a 1 chain structure. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=6WIB OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=6WIB FirstGlance]. <br>

</td></tr><tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=6wib FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=6wib OCA], [https://pdbe.org/6wib PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=6wib RCSB], [https://www.ebi.ac.uk/pdbsum/6wib PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=6wib ProSAT]</span></td></tr>

</td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=BMA:BETA-D-MANNOSE'>BMA</scene>, <scene name='pdbligand=ZN:ZINC+ION'>ZN</scene>, <scene name='pdbligand=FUC:ALPHA-L-FUCOSE'>FUC</scene>, <scene name='pdbligand=MAN:ALPHA-D-MANNOSE'>MAN</scene>, <scene name='pdbligand=NAG:N-ACETYL-D-GLUCOSAMINE'>NAG</scene></td></tr>

<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=6wib FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=6wib OCA], [https://pdbe.org/6wib PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=6wib RCSB], [https://www.ebi.ac.uk/pdbsum/6wib PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=6wib ProSAT]</span></td></tr>

</table>

== Publication Abstract from PubMed ==

In a biologic therapeutic landscape that requires versatility in targeting specificity, valency and half-life modulation, the monomeric Fc fusion platform holds exciting potential for the creation of a class of monovalent protein therapeutics that includes fusion proteins and bispecific targeting molecules. Here we report a structure-guided approach to engineer monomeric Fc molecules to adapt multiple versions of half-life extension modifications. Co-crystal structures of these monomeric Fc variants with Fc neonatal receptor (FcRn) shed light into the binding interactions that could serve as a guide for engineering the half-life of antibody Fc fragments. These engineered monomeric Fc molecules also enabled the generation of a novel monovalent bispecific molecular design, which translated the FcRn binding enhancement to improvement of in vivo serum half-life.

In vivo pharmacokinetic enhancement of monomeric Fc and monovalent bispecific designs through structural guidance.,Shan L, Dyk NV, Haskins N, Cook KM, Rosenthal KL, Mazor R, Dragulin-Otto S, Jiang Y, Wu H, Dall'Acqua WF, Borrok MJ, Damschroder MM, Oganesyan V Commun Biol. 2021 Sep 8;4(1):1048. doi: 10.1038/s42003-021-02565-5. PMID:34497355<ref>PMID:34497355</ref>

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.<br>

</div>

== References ==

__TOC__

</StructureSection>

[[Category: Large Structures]]

[[Category: ~~Dall'~~Acqua W]]

[[Category: Acqua, W Dall]]

[[Category: Oganesyan VY]]

[[Category: Dyk, N van]]

[[Category: Shan L]]

[[Category: Oganesyan, V Y]]

[[Category: ~~Van Dyk N~~]]

[[Category: Shan, L]]

[[Category: Antibody constant region]]

[[Category: Fragment crystallizable]]

[[Category: Immune system]]

[[Category: Mutated]]

Navigation menu

Page actions

Page actions

Personal tools

Navigation

Search

Tools

@@ Line 1: / Line 1: @@
 ==Next generation monomeric IgG4 Fc==
-<StructureSection load='6wib' size='340' side='right'caption='[[6wib]]' scene=''>
+<StructureSection load='6wib' size='340' side='right'caption='[[6wib]], [[Resolution|resolution]] 2.55&Aring;' scene=''>
 == Structural highlights ==
-<table><tr><td colspan='2'>Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=6WIB OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=6WIB FirstGlance]. <br>
+<table><tr><td colspan='2'>[[6wib]] is a 1 chain structure. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=6WIB OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=6WIB FirstGlance]. <br>
-</td></tr><tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=6wib FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=6wib OCA], [https://pdbe.org/6wib PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=6wib RCSB], [https://www.ebi.ac.uk/pdbsum/6wib PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=6wib ProSAT]</span></td></tr>
+</td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=BMA:BETA-D-MANNOSE'>BMA</scene>, <scene name='pdbligand=ZN:ZINC+ION'>ZN</scene>, <scene name='pdbligand=FUC:ALPHA-L-FUCOSE'>FUC</scene>, <scene name='pdbligand=MAN:ALPHA-D-MANNOSE'>MAN</scene>, <scene name='pdbligand=NAG:N-ACETYL-D-GLUCOSAMINE'>NAG</scene></td></tr>
+<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=6wib FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=6wib OCA], [https://pdbe.org/6wib PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=6wib RCSB], [https://www.ebi.ac.uk/pdbsum/6wib PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=6wib ProSAT]</span></td></tr>
 </table>
+<div style="background-color:#fffaf0;">
+== Publication Abstract from PubMed ==
+In a biologic therapeutic landscape that requires versatility in targeting specificity, valency and half-life modulation, the monomeric Fc fusion platform holds exciting potential for the creation of a class of monovalent protein therapeutics that includes fusion proteins and bispecific targeting molecules. Here we report a structure-guided approach to engineer monomeric Fc molecules to adapt multiple versions of half-life extension modifications. Co-crystal structures of these monomeric Fc variants with Fc neonatal receptor (FcRn) shed light into the binding interactions that could serve as a guide for engineering the half-life of antibody Fc fragments. These engineered monomeric Fc molecules also enabled the generation of a novel monovalent bispecific molecular design, which translated the FcRn binding enhancement to improvement of in vivo serum half-life.
+In vivo pharmacokinetic enhancement of monomeric Fc and monovalent bispecific designs through structural guidance.,Shan L, Dyk NV, Haskins N, Cook KM, Rosenthal KL, Mazor R, Dragulin-Otto S, Jiang Y, Wu H, Dall'Acqua WF, Borrok MJ, Damschroder MM, Oganesyan V Commun Biol. 2021 Sep 8;4(1):1048. doi: 10.1038/s42003-021-02565-5. PMID:34497355<ref>PMID:34497355</ref>
+From MEDLINE&reg;/PubMed&reg;, a database of the U.S. National Library of Medicine.<br>
+</div>
+<div class="pdbe-citations 6wib" style="background-color:#fffaf0;"></div>
+== References ==
+<references/>
 __TOC__
 </StructureSection>
 [[Category: Large Structures]]
-[[Category: Dall'Acqua W]]
+[[Category: Acqua, W Dall]]
-[[Category: Oganesyan VY]]
+[[Category: Dyk, N van]]
-[[Category: Shan L]]
+[[Category: Oganesyan, V Y]]
-[[Category: Van Dyk N]]
+[[Category: Shan, L]]
+[[Category: Antibody constant region]]
+[[Category: Fragment crystallizable]]
+[[Category: Immune system]]
+[[Category: Mutated]]